This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Organon (OGN) Receives a Sell from Piper Sandler

Tipranks - Tipranks - Fri Apr 24, 6:51AM CDT

In a report released today, David Amsellem from Piper Sandler maintained a Sell rating on Organon, with a price target of $5.00.

Claim 30% Off TipRanks

According to TipRanks, Amsellem is a 5-star analyst with an average return of 8.3% and a 52.91% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as AbbVie, Amgen, and Esperion.

Currently, the analyst consensus on Organon is a Moderate Sell with an average price target of $10.75.

See today’s best-performing stocks on TipRanks >>

Based on Organon’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.51 billion and a GAAP net loss of $205 million. In comparison, last year the company earned a revenue of $1.59 billion and had a net profit of $109 million

Read More on OGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).